Kyverna Seeks Historic Regulatory Approval for First-Ever Autoimmune Cell Therapy

2026-11-13 companies

Emeryville, Friday, 13 November 2026.
Kyverna completed its application for miv-cel to treat stiff person syndrome, targeting a 2027 launch that could establish the first approved therapy capable of reversing disability in this rare disorder.

Historic BLA Submission for First Autoimmune CAR-T Therapy

On November 11-12, 2026, Kyverna Therapeutics (NASDAQ: KYTX) achieved a historic regulatory milestone by completing its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration for miv-cel (mivocabtagene autoleucel, KYV-101) in Stiff Person Syndrome (SPS). The company simultaneously requested priority review under the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation [1][2][3][5][7]. This submission represents the first-ever BLA for a CAR-T cell therapy targeting an autoimmune disease, positioning miv-cel as a potential breakthrough treatment for the estimated 1-2 cases per million people worldwide affected by SPS [GPT].

Clinical Data Supporting Regulatory Submission

The BLA submission is underpinned by robust clinical data from the Phase 2 KYSA-8 trial, which enrolled 26 adult patients treated with a single dose of miv-cel. The study demonstrated a median walking-time improvement of 46% at 16 weeks and 49% at one year (p < 0.0001), with durability confirmed in October 2026 presentations at MS Toronto [3][5]. Notably, the trial showed no high-grade cytokine release syndrome or immune effector cell-associated neurotoxicity, with manageable safety profiles including five cases of grade 3-4 neutropenia and three serious treatment-related adverse events that all resolved [3].

Financial Position and Commercial Readiness

Kyverna reported $170.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, providing an operating runway extending into 2028 through its amended Oxford Finance loan facility [1][2][3][5][8]. The company’s Q3 2026 financial results showed a net loss of $41.9 million (or $0.68 per share), with Research and Development expenses of $27.0 million and General and Administrative expenses of $15.9 million [1][2][3][5][8]. Commercial readiness activities are advancing in anticipation of a potential 2027 launch, with field sales and medical specialist recruitment already underway [3][5].

Pipeline Expansion and Regulatory Pathways

Miv-cel has received three FDA RMAT designations covering SPS, generalized myasthenia gravis (gMG), and non-active secondary progressive multiple sclerosis (naSPMS), establishing multiple potential regulatory pathways [1][2][3][5]. Kyverna’s development strategy includes the ongoing KYSA-6 Phase 3 trial for gMG, with enrollment on track for completion in mid-2027 [1][2][3][5]. The company has deprioritized its KYV-102 program to focus resources on neurologic indications, including plans to share its progressive multiple sclerosis development strategy by early 2027 [2][5].

Market Impact and Investor Sentiment

Following the BLA submission announcement, Kyverna’s shares closed at $5.12 on November 11, 2026, reflecting investor optimism about the potential first approval in a therapeutic area lacking any existing treatments [3]. Institutional activity has been mixed, with major firms like BlackRock increasing positions by 257.4% in Q2 2026, while others like Marshall Wace and Susquehanna reduced exposure [4]. Analysts note that miv-cel’s clinical profile and manufacturing capabilities could support a strong commercial launch in SPS if approved, given the current absence of FDA-approved therapies for this condition [3][alert! ‘Trading data reflects short-term volatility rather than long-term fundamentals’].

Sources

Biotechnology Pharmaceuticals